ArticleFrontiers in neurology
Neutrophil-to-apolipoprotein A1 ratio as a novel biomarker for prognosis in anti-NMDAR encephalitis: a retrospective cohort analysis.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the correlation between the neutrophil-to-apolipoprotein A1 ratio (NAR) and disease severity, long-term prognosis, and risk of relapse in patients with anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. Methods: This study included 125 patients with anti-NMDAR encephalitis as a retrospective cohort. Baseline clinical, laboratory, and imaging data was collected. Spearman's correlation analysis was used to evaluate correlations between NAR, disease severity, and C-reactive protein (CRP) levels. Logistic regression and Cox proportional hazards models were used to analyze independent associations between NAR and poor prognosis and recurrence, respectively. The predictive performance of NAR was evaluated using receiver operating characteristic (ROC) curves. Mediation analysis was used to explore potential pathways of action. Sensitivity and subgroup analyses were performed to verify the reliability of the results. Results: The final modified Rankin's score (mRS) score and recurrence rate were significantly higher in the high-NAR group than in the low-NAR group (both Conclusion: NAR is an independent predictor of poor disease prognosis and risk of recurrence in patients with anti-NMDAR encephalitis. Its high specificity helps identify high-risk patients early and accurately, giving this biomarker long-term prognostic value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.